Health Care·Pharmaceuticals·$3.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -$0.14 | N/A | +10.83% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | -$0.14 | N/A | +10.83% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed a cautious optimism about their pipeline and future developments. They noted the significance of upcoming milestones.
Management highlighted ongoing progress in their clinical trials.
They emphasized the importance of upcoming data releases for future growth.
Edgewise Therapeutics reported a narrower loss than expected, which is a positive sign for investors. However, the stock fell by 4.29% in reaction, likely due to the lack of revenue information and guidance. Investors may be concerned about the company's future prospects without clear direction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AIR PRODS & CHEMS IN
May 10, 2021